



2021 Vol.15(13)



# TB ALERT

(a fortnightly publication from NIRT Library)

ICMR-National Institute for Research in Tuberculosis



1. Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets: Worldwide, 2019. *Pediatr Infect Dis J.* 2021;40(8):752. <https://www.ncbi.nlm.nih.gov/pubmed/34250974>.
2. The Cost of Tuberculosis. *JAMA.* 2021;326(1):92. <https://www.ncbi.nlm.nih.gov/pubmed/34228073>.
3. Corrigendum to "Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients". *Glob Pediatr Health.* 2021;8:2333794X211023462. <https://www.ncbi.nlm.nih.gov/pubmed/34222564>.
4. Adams O, Deme JC, Parker JL, Consortium CR, Fowler PW, Lea SM, et al. Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target. *Structure.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34242558>.
5. Ai X, Huang H, Miao Z, Zhou T, Wu H, Lai Y. Relationship between xanthine oxidase gene polymorphisms and anti-tuberculosis drug-induced liver injury in a Chinese population. *Infect Genet Evol.* 2021;93:104991. <https://www.ncbi.nlm.nih.gov/pubmed/34229066>.
6. Alagna R, Cabibbe AM, Miotto P, Saluzzo F, Koser CU, Niemann S, et al. Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice? *Eur Respir J.* 2021;58(1). <https://www.ncbi.nlm.nih.gov/pubmed/34215664>.
7. Aldridge BB, Barros-Aguirre D, Barry CE, 3rd, Bates RH, Berthel SJ, Boshoff HI, et al. The Tuberculosis Drug Accelerator at year 10: what have we learned? *Nat Med.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34226736>.
8. Alene KA, Xu Z, Bai L, Yi H, Tan Y, Gray DJ, et al. Spatiotemporal Patterns of Tuberculosis in Hunan Province, China. *Int J Environ Res Public Health.* 2021;18(13). <https://www.ncbi.nlm.nih.gov/pubmed/34202504>.
9. Almagaw G, Conlan AJK, Ameni G, Gumi B, Alemu A, Guta S, et al. The variable prevalence of bovine tuberculosis among dairy herds in Central Ethiopia provides opportunities for targeted intervention. *PLoS One.* 2021;16(7):e0254091. <https://www.ncbi.nlm.nih.gov/pubmed/34214106>.
10. Al-Shahrani MS, Hakami MI, Younis MA, Fan HA, Jeraiby MA, Alraey Y. Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors. *Saudi Med J.* 2021;42(7):728-34. <https://www.ncbi.nlm.nih.gov/pubmed/34187916>.
11. Al-Zanbagi AB, Shariff MK. Gastrointestinal tuberculosis: A systematic review of epidemiology, presentation, diagnosis and treatment. *Saudi J Gastroenterol.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34213424>.
12. Anand C, Santoshi M, Singh PR, Nagaraja V. Rv0802c is an acyltransferase that succinylates and acetylates Mycobacterium tuberculosis nucleoid-associated protein HU. *Microbiology (Reading).* 2021;167(7). <https://www.ncbi.nlm.nih.gov/pubmed/34224344>.

13. Araia ZZ, Mesfin AB, Mebrahtu AH, Tewelde AG, Tewelde AT, Ngusbrhan Kidane S. Health-Related Quality of Life in Tuberculosis Patients in Eritrea: Comparison Among Drug-Susceptible and Rifampicin/Multidrug-Resistant Tuberculosis Patients. *Patient Relat Outcome Meas.* 2021;12:205-12. <https://www.ncbi.nlm.nih.gov/pubmed/34234605>.
14. Ardhianto D, Suharjono, Soedarsono, Fatmawati U. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. *J Basic Clin Physiol Pharmacol.* 2021;32(4):421-7. <https://www.ncbi.nlm.nih.gov/pubmed/34214323>.
15. Baik Y, Hanrahan CF, Mmolawa L, Nonyane BAS, Albaugh NW, Lebina L, et al. Conditional cash transfers to incentivize tuberculosis screening: Description of a novel strategy for contact investigation in rural South Africa. *Clin Infect Dis.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34212181>.
16. Bajaj AO, Saraswat S, Knuuttila JEA, Freeke J, Stielow JB, Barker AP. Accurate Identification of Closely Related Mycobacterium tuberculosis Complex Species by High Resolution Tandem Mass Spectrometry. *Front Cell Infect Microbiol.* 2021;11:656880. <https://www.ncbi.nlm.nih.gov/pubmed/34239815>.
17. Baluku JB, Katuramu R, Naloka J, Kizito E, Nabwana M, Bongomin F. Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda. *BMC Pulm Med.* 2021;21(1):220. <https://www.ncbi.nlm.nih.gov/pubmed/34246234>.
18. Bayaa R, Ndiaye MDB, Chedid C, Kokhraidze E, Tukvadze N, Banu S, et al. Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. *Sci Rep.* 2021;11(1):13646. <https://www.ncbi.nlm.nih.gov/pubmed/34211042>.
19. Bell SL, Lopez KL, Cox JS, Patrick KL, Watson RO. Galectin-8 Senses Phagosomal Damage and Recruits Selective Autophagy Adapter TAX1BP1 To Control Mycobacterium tuberculosis Infection in Macrophages. *mBio.* 2021:e0187120. <https://www.ncbi.nlm.nih.gov/pubmed/34225486>.
20. Benaissa E, Marjane S, Bssaibis F, Benlahlou Y, Chadli M, Maleb A, et al. A Case of Colonic Tuberculosis Revealed by Polymerase Chain Reaction. *Clin Lab.* 2021;67(7). <https://www.ncbi.nlm.nih.gov/pubmed/34258976>.
21. Bertlich M, Paparoupa M, Weckauf H, Wittig A, Linnemuller S, Schuppert F. The diagnostic challenge of abdominal tuberculosis in nonendemic countries: A case series from a tertiary hospital in Germany. *Clin Case Rep.* 2021;9(7):e04524. <https://www.ncbi.nlm.nih.gov/pubmed/34257992>.
22. Bhargava A, Bhargava M, Meher A. Universal health coverage and tuberculosis care in India in the times of Covid-19: Aligning Ayushman Bharat (National Health Assurance Scheme) to improve case detection, reduce deaths and catastrophic health expenditure. *Natl Med J India.* 2020;33(5):298-301. <https://www.ncbi.nlm.nih.gov/pubmed/34213460>.

23. Boah M, Kpordoxah MR, Adokiya MN. Self-reported gender differentials in the knowledge of tuberculosis transmission and curative possibility using national representative data in Ghana. *PLoS One*. 2021;16(7):e0254499. <https://www.ncbi.nlm.nih.gov/pubmed/34252131>.
24. Bokolia NP, Khan IA. Regulation of polyphosphate glucokinase gene expression through co-transcriptional processing in Mycobacterium tuberculosis H37Rv. *J Biochem*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34247237>.
25. Brandenburg J, Marwitz S, Tazoll SC, Waldow F, Kalsdorf B, Vierbuchen T, et al. WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis. *J Clin Invest*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34255743>.
26. Brandi N, Bartalena L, Mosconi C, Golfieri R. A unique case of miliary pulmonary tuberculosis induced by bacillus Calmette-Guerin intravesical instillation with COVID-19 superinfection. *SA J Radiol*. 2021;25(1):2122. <https://www.ncbi.nlm.nih.gov/pubmed/34230863>.
27. Brett K, Severn M. Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings. CADTH Health Technology Review. *Ottawa (ON)*2021. <https://www.ncbi.nlm.nih.gov/pubmed/34260164>.
28. Brown AC. Whole-Genome Sequencing of Mycobacterium tuberculosis Directly from Sputum Samples. *Methods Mol Biol*. 2021;2314:459-80. <https://www.ncbi.nlm.nih.gov/pubmed/34235666>.
29. Bustamante-Rengifo JA, Astudillo-Hernandez M, Del Pilar Crespo-Ortiz M. Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis. *Curr Microbiol*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34251513>.
30. Campbell JR, Schwartzman K. The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination. *Am J Epidemiol*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34216207>.
31. Cazarez-Navarro G, Palomares-Marin J, Rodriguez-Preciado SY, Pereira-Suarez AL, Martinez-Lopez E, Bacilio-Medrano EA, et al. Association of TAP1 1177A>G and 2090A>G gene polymorphisms with latent tuberculosis infections in sheltered populations, in the metropolitan area of Guadalajara, Mexico: a pilot study. *Rev Inst Med Trop Sao Paulo*. 2021;63:e55. <https://www.ncbi.nlm.nih.gov/pubmed/34231820>.
32. Chen Y, Ge P, Zhang K, Xiang J, Zhang L, Robertson ID, et al. Use of Rv0222-Rv2657c-Rv1509 Fusion Protein to Improve the Accuracy of an Antibody ELISA for Extra-Pulmonary Tuberculosis in Humans. *Pathogens*. 2021;10(7). <https://www.ncbi.nlm.nih.gov/pubmed/34209358>.
33. Chidambaram V, Zhou L, Ruelas Castillo J, Kumar A, Ayeh SK, Gupte A, et al. Higher Serum Cholesterol Levels Are Associated With Reduced Systemic Inflammation and Mortality During Tuberculosis Treatment Independent of Body Mass Index. *Front Cardiovasc Med*. 2021;8:696517. <https://www.ncbi.nlm.nih.gov/pubmed/34239907>.

34. Chinnadurai A. Treatment adherence to tuberculosis: What works. *Natl Med J India*. <https://www.ncbi.nlm.nih.gov/pubmed/34213457>.2020;33(5):288-9.
35. Comella-Del-Barrio P, Bimba JS, Adalokun R, Kontogianni K, Molina-Moya B, Osazuwa O, et al. Fujifilm SILVAMP TB-LAM for the Diagnosis of Tuberculosis in Nigerian Adults. *J Clin Med*. 2021;10(11). <https://www.ncbi.nlm.nih.gov/pubmed/34204120>.
36. Costa CM, Gadotti LL, Seiwald MC, Salgues ACR, Ganem F, Nascimento ECT, et al. Ganglionar tuberculosis infection evolving to hemophagocytic lymphohistiocytosis after anti-programmed cell death 1 treatment for high-risk melanoma: a case report. *J Med Case Rep*. 2021;15(1):350. <https://www.ncbi.nlm.nih.gov/pubmed/34233733>.
37. Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Andrade BB, Sher A. Enhancement of CD4(+) T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work? *Front Cell Infect Microbiol*. 2021;11:672527. <https://www.ncbi.nlm.nih.gov/pubmed/34235093>.
38. Crececius EM, Lustik MB, Horseman TS, Jones MU. The prevalence of M. tuberculosis among acid fast bacilli cultures from military health system and veterans affairs beneficiaries in Hawaii and the Pacific Islands from 2002 to 2019. *PLoS One*. 2021;16(7):e0254312. <https://www.ncbi.nlm.nih.gov/pubmed/34242307>.
39. Cress V, Kwon SMS, Ulrich MT. All Signs Point to Cancer: A Case of Cryptic Miliary Tuberculosis in the Setting of Concomitant Cancer. *Case Rep Infect Dis*. 2021;2021:4623086. <https://www.ncbi.nlm.nih.gov/pubmed/34188962>.
40. Cuong NK, Ngoc NB, Hoa NB, Dat VQ, Nhung NV. GeneXpert on patients with human immunodeficiency virus and smear-negative pulmonary tuberculosis. *PLoS One*. 2021;16(7):e0253961. <https://www.ncbi.nlm.nih.gov/pubmed/34228759>.
41. da Silva Leite JM, Patriota YBG, de La Roca MF, Soares-Sobrinho JL. New Perspectives in Drug Delivery Systems for the Treatment of Tuberculosis. *Curr Med Chem*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34212827>.
42. Das R, Eniyan K, Bajpai U. Computational identification and characterization of antigenic properties of Rv3899c of Mycobacterium tuberculosis and its interaction with human leukocyte antigen (HLA). *Immunogenetics*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34228167>.
43. Das S, Marin ND, Esaulova E, Ahmed M, Swain A, Rosa BA, et al. Lung Epithelial Signaling Mediates Early Vaccine-Induced CD4(+) T Cell Activation and Mycobacterium tuberculosis Control. *mBio*. 2021:e0146821. <https://www.ncbi.nlm.nih.gov/pubmed/34253059>.
44. Dawit Z, Abebe S, Dessu S, Mesele M, Sahile S, Ajema D. Incidence and predictors of mortality among children co-infected with tuberculosis and human immunodeficiency virus at public hospitals in Southern Ethiopia. *PLoS One*. 2021;16(6):e0253449. <https://www.ncbi.nlm.nih.gov/pubmed/34191846>.

45. Deboosere N, Belhaouane I, Machelart A, Hoffmann E, Vandeputte A, Brodin P. High-Content Analysis Monitoring Intracellular Trafficking and Replication of Mycobacterium tuberculosis Inside Host Cells. *Methods Mol Biol.* 2021;2314:649-702. <https://www.ncbi.nlm.nih.gov/pubmed/34235675>.
46. Devalraju KP, Tripathi D, Neela VSK, Paidipally P, Radhakrishnan RK, Singh KP, et al. Reduced thyroxine production in young household contacts of tuberculosis patients increases active tuberculosis disease risk. *JCI Insight.* 2021;6(13). <https://www.ncbi.nlm.nih.gov/pubmed/34236051>.
47. Dowdy D. Refocusing the timeline of tuberculosis through the lens of BCG. *Thorax.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34226207>.
48. Ealand C, Peters J, Jacobs O, Sewcharran A, Ghoor A, Golub J, et al. Detection of Mycobacterium tuberculosis Complex Bacilli and Nucleic Acids From Tongue Swabs in Young, Hospitalized Children. *Front Cell Infect Microbiol.* 2021;11:696379. <https://www.ncbi.nlm.nih.gov/pubmed/34195103>.
49. Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant GJ, et al. Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits. *Antimicrob Agents Chemother.* 2021:AAC0002421. <https://www.ncbi.nlm.nih.gov/pubmed/34228540>.
50. Elbert JA, Sanchez S, Rissi DR. Metastatic cholangiocarcinoma mimicking tuberculosis in a cow. *J Vet Diagn Invest.* 2021:10406387211029904. <https://www.ncbi.nlm.nih.gov/pubmed/34235998>.
51. Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD, Strydom N, et al. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. *Antimicrob Agents Chemother.* 2021:AAC0050621. <https://www.ncbi.nlm.nih.gov/pubmed/34252307>.
52. Fan S, Zhuang J, Guo C, Lin D, Liao X. (1)H, (13)C, (15)N backbone and side-chain chemical shift assignments of the polyketide cyclase from Mycobacterium tuberculosis. *Biomol NMR Assign.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34247331>.
53. Fang G, Cheng NC, Huang LL, Xie WP, Hu CM, Chen W. The first report of co-existence of pulmonary tuberculosis and lung malignancy in a kidney transplant recipient: a case report and literature review. *BMC Infect Dis.* 2021;21(1):629. <https://www.ncbi.nlm.nih.gov/pubmed/34210287>.
54. Fang L, Gong Y, Han K, Lv Y, Li M, Wang J. Longitudinally extensive transverse myelitis with mycobacterium tuberculosis infection. *Acta Neurol Belg.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34224079>.
55. Fatima S, Syeda MF, Adla N, Devi R. Ambispective study of adverse drug reactions in multi-drug resistant tuberculosis patients in Warangal, Telangana. *Lung India.* 2021;38(4):330-7. <https://www.ncbi.nlm.nih.gov/pubmed/34259171>.

56. Fehr J, Konigorski S, Olivier S, Gunda R, Surujdeen A, Gareta D, et al. Computer-aided interpretation of chest radiography reveals the spectrum of tuberculosis in rural South Africa. *NPJ Digit Med.* 2021;4(1):106. <https://www.ncbi.nlm.nih.gov/pubmed/34215836>.
57. Filipek-Czerska A, Karczewski JK, Gladysz I. [Latent tuberculosis infection in the Polish prison staff]. *Med Pr.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34254590>.
58. Foley DA, Phuong LK, Globan M, Fyfe JM, Lavender C, Williamson DA. The performance of the Xpert MTB/RIF Version G4 in a low tuberculosis incidence setting. *Pathology.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34218951>.
59. Fonseca CA, Jr., Zanetti G, Marchiori E. Pulmonary Tuberculosis in a Patient with COVID-19 Pneumonia. *Rev Soc Bras Med Trop.* 2021;54:e03142021. <https://www.ncbi.nlm.nih.gov/pubmed/34231776>.
60. Gazel D, Zapanalioglu Gazel O. In vitro activity of methylene blue on Mycobacterium tuberculosis complex isolates. *Tuberk Toraks.* 2021;69(2):279-84. <https://www.ncbi.nlm.nih.gov/pubmed/34256520>.
61. Getnet F, Demissie M, Worku A, Gobena T, Tschopp R, Farah AM, et al. Challenges in delivery of tuberculosis Services in Ethiopian Pastoralist Settings: clues for reforming service models and organizational structures. *BMC Health Serv Res.* 2021;21(1):627. <https://www.ncbi.nlm.nih.gov/pubmed/34193133>.
62. Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, et al. A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2021:AAC0179420. <https://www.ncbi.nlm.nih.gov/pubmed/34252302>.
63. Giacalone D, Huang L, Tan S. Exploiting Fluorescent Proteins to Understand Mycobacterium tuberculosis Biology. *Methods Mol Biol.* 2021;2314:365-83. <https://www.ncbi.nlm.nih.gov/pubmed/34235663>.
64. Gilmour B, Alene KA, Clarke NE, Clements ACA. The prevalence of tuberculosis, malaria and soil-transmitted helminth infection in minority indigenous people of Southeast Asia and the Western Pacific: protocol for a systematic review and meta-analysis. *Syst Rev.* 2021;10(1):203. <https://www.ncbi.nlm.nih.gov/pubmed/34246316>.
65. Gold B, Warriar T, Nathan C. A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis. *Methods Mol Biol.* 2021;2314:611-35. <https://www.ncbi.nlm.nih.gov/pubmed/34235673>.
66. Gomez M, McCollum J, Wang H, Bachchhav S, Tetreau I, Gerhardt A, et al. Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery. *Vaccine.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34256969>.

67. Gong Z, Gu Y, Xiong K, Niu J, Zheng R, Su B, et al. The Evaluation and Validation of Blood-Derived Novel Biomarkers for Precise and Rapid Diagnosis of Tuberculosis in Areas With High-TB Burden. *Front Microbiol.* 2021;12:650567. <https://www.ncbi.nlm.nih.gov/pubmed/34194403>.
68. Guha M, Lal H, Boruah T, Kumar S, Sareen A, Patralekh MK, et al. Clinico-Radio-Histopathological Correlation by C-Arm Image-Guided Biopsy in Spinal Tuberculosis. *Indian J Orthop.* 2021;55(4):1028-36. <https://www.ncbi.nlm.nih.gov/pubmed/34194661>.
69. Gupta P, Thomas SE, Zaidan SA, Pasillas MA, Cory-Wright J, Sebastian-Perez V, et al. A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis. *Comput Struct Biotechnol J.* 2021;19:3491-506. <https://www.ncbi.nlm.nih.gov/pubmed/34194673>.
70. Hacıoglu A, Borekci S, Melikoglu M, Ozguler Y, Esatoglu SN, Ugurlu S, et al. Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. *Rheumatol Int.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34228162>.
71. Hadizadeh Tasbiti A, Yari S, Siadat SD, Karimipoor M, Badmasti F, Masoumi M, et al. Comparing mRNA expression and protein abundance in MDR Mycobacterium tuberculosis: Novel protein candidates, Rv0443, Rv0379 and Rv0147 as TB potential diagnostic or therapeutic targets. *Biotechnol Rep (Ams).* 2021;30:e00641. <https://www.ncbi.nlm.nih.gov/pubmed/34189062>.
72. Hamzah MH, Mohamad I, Mutalib NSA. Primary Eustachian Tube Tuberculosis. *Medeni Med J.* 2021;36(2):172-5. <https://www.ncbi.nlm.nih.gov/pubmed/34234985>.
73. Han J, Ning P, Ge A, Ma X, Burton JA, Yang C, et al. Corrigendum to "Association of polymorphisms of innate immunity-related genes and tuberculosis susceptibility in Mongolian population" [Hum. Immunol. 82(4) (2021) 232-239]. *Hum Immunol.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34243990>.
74. Harandi TF, Mahmoodi Z, Ghavidel N, Sharifipour Z. Factors affecting self-management in Iranian tuberculosis patients: A path analysis model. *Can J Respir Ther.* 2021;57:73-8. <https://www.ncbi.nlm.nih.gov/pubmed/34212074>.
75. Harries AD, Thekkur P, Mbithi I, Chakaya JM, Tweya H, Takarinda KC, et al. Real-Time Operational Research: Case Studies from the Field of Tuberculosis and Lessons Learnt. *Trop Med Infect Dis.* 2021;6(2). <https://www.ncbi.nlm.nih.gov/pubmed/34201324>.
76. Hase I, Toren KG, Hirano H, Sakurai K, Horne DJ, Saito T, et al. Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation. *Drugs Aging.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34224105>.
77. He W, Liu C, Liu D, Ma A, Song Y, He P, et al. Prevalence of Mycobacterium tuberculosis resistant to Bedaquiline and Delamanid in China. *J Glob Antimicrob Resist.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34214699>.



78. Hillery N, Seifert M, Catanzaro DG, McKinnon S, Colman RE, Chiles PG, et al. Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study. *JMIR Res Protoc*. 2021;10(7):e26748. <https://www.ncbi.nlm.nih.gov/pubmed/34259165>.
79. Hoheisel A, Vogt G, Nagel S, Bonitz A, Muller C, Kohnlein T, et al. [MDR tuberculosis, Alpha-1-anti-trypsin Deficiency, Cough in a Geriatric Nurse]. *Pneumologie*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34233361>.
80. Holzheimer M, Buter J, Minnaard AJ. Chemical Synthesis of Cell Wall Constituents of *Mycobacterium tuberculosis*. *Chem Rev*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34190544>.
81. Interlandi E, Pellegrini F, Pavesio C, De Luca M, De Marco R, Papayannis A, et al. Intraocular Tuberculosis: A Challenging Case Mimicking Wet Age-Related Macular Degeneration. *Case Rep Ophthalmol*. 2021;12(2):519-24. <https://www.ncbi.nlm.nih.gov/pubmed/34248585>.
82. Isaguliants M, Nosik M, Karlsen A, Petrakova N, Enaeva M, Lebedeva N, et al. Prevalence and Risk Factors of Infection with High Risk Human Papilloma Viruses among HIV-Positive Women with Clinical Manifestations of Tuberculosis in a Middle-Income Country. *Biomedicines*. 2021;9(6). <https://www.ncbi.nlm.nih.gov/pubmed/34208764>.
83. Jain NK. WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry? *Lung India*. 2021;38(4):303-6. <https://www.ncbi.nlm.nih.gov/pubmed/34259166>.
84. Jiang H, Cui B, Zhang J. *Mycobacterium tuberculosis* (MTB) antigen-induced upregulation of interleukin-35 expression in patients with MTB infection: In vitro blockade of the effects of interleukin-35 on T lymphocyte subsets. *Pathog Dis*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34245560>.
85. Johnson BK, Thomas SM, Olive AJ, Abramovitch RB. Macrophage Infection Models for *Mycobacterium tuberculosis*. *Methods Mol Biol*. 2021;2314:167-82. <https://www.ncbi.nlm.nih.gov/pubmed/34235652>.
86. Joseph Y, Yao Z, Dua A, Severe P, Collins SE, Bang H, et al. Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti. *J Int AIDS Soc*. 2021;24(7):e25721. <https://www.ncbi.nlm.nih.gov/pubmed/34235862>.
87. Kalla IS, Miri A, Seedat F. Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. *Afr J Thorac Crit Care Med*. 2020;26(4). <https://www.ncbi.nlm.nih.gov/pubmed/34240037>.
88. Kapp E, Joubert J, Sampson SL, Warner DF, Seldon R, Jordaan A, et al. Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against *Mycobacterium tuberculosis*. *Adv Pharmacol Pharm Sci*. 2021;2021:5583342. <https://www.ncbi.nlm.nih.gov/pubmed/34240057>.

89. Kassa GM, Merid MW, Muluneh AG. Khat Chewing and Clinical Conditions Determine the Epidemiology of Primary Drug Resistance Tuberculosis in Amhara Region of Ethiopia: A Multicenter Study. *Infect Drug Resist.* 2021;14:2449-60. <https://www.ncbi.nlm.nih.gov/pubmed/34234475>.
90. Kaur P, Potluri V, Ahuja VK, Naveenkumar CN, Krishnamurthy RV, Gangadharaiah ST, et al. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. *Tuberculosis (Edinb)*. 2021;129:102104. <https://www.ncbi.nlm.nih.gov/pubmed/34214859>.
91. Kechaou I, Abida R, Hamdi MS, Hassine LB. Palate Tuberculosis with Paradoxical Lymphadenitis. *J Glob Infect Dis.* 2021;13(2):94-6. <https://www.ncbi.nlm.nih.gov/pubmed/34194177>.
92. Khan AS, Phelan JE, Khan MT, Ali S, Qasim M, Napier G, et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. *Sci Rep.* 2021;11(1):14194. <https://www.ncbi.nlm.nih.gov/pubmed/34244539>.
93. Kholto bin DP, Kulchavenya EV. [Surgical treatment of patients with urogenital tuberculosis]. *Urologiia.* 2021(3):155-61. <https://www.ncbi.nlm.nih.gov/pubmed/34251118>.
94. Khosrobeygi M, Mosavari N, Salehi M, Mojjani N, Akbari M. Isolation and Purification of Low Molecular Weight Proteins from Culture Filtrate of Mycobacterium Tuberculosis Strain C. *Arch Razi Inst.* 2021;76(2):273-81. <https://www.ncbi.nlm.nih.gov/pubmed/34223726>.
95. Khundi M, Carpenter JR, Nliwasa M, Cohen T, Corbett EL, MacPherson P. Effectiveness of spatially targeted interventions for control of HIV, tuberculosis, leprosy and malaria: a systematic review. *BMJ Open.* 2021;11(7):e044715. <https://www.ncbi.nlm.nih.gov/pubmed/34257091>.
96. Kim HW, Shin AY, Ha JH, Ahn JH, Kang HS, Kim JS. Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response - A retrospective cohort study. *J Infect Chemother.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34238662>.
97. Kim SK, Alarj M, Yang H, Jundi M. Biportal endoscopic debridement and percutaneous screw fixation technique for spinal tuberculosis: how I do it. *Acta Neurochir (Wien)*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34240248>.
98. Kirubi B, Ong'ang'o J, Nguhiu P, Lonroth K, Rono A, Sidney-Annerstedt K. Determinants of household catastrophic costs for drug sensitive tuberculosis patients in Kenya. *Infect Dis Poverty.* 2021;10(1):95. <https://www.ncbi.nlm.nih.gov/pubmed/34225790>.
99. Kloprogge F, Abubakar I, Esmail H, Hack V, Kunst H, McHugh TD, et al. Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. *BMJ Open.* 2021;11(7):e052885. <https://www.ncbi.nlm.nih.gov/pubmed/34244287>.
100. Korkmaz MC, Tolu S, Simsek S. A Rare Case of Flexor Tenosynovitis Due to Tuberculosis in Hand and Wrist: a Case Report. *Acta Chir Orthop Traumatol Cech.* 2021;88(3):237-9. <https://www.ncbi.nlm.nih.gov/pubmed/34228622>.

101. Kuchukhidze G, Baliashvili D, Adamashvili N, Kasradze A, Kempker RR, Magee MJ. Long-Term Mortality and Active Tuberculosis Disease Among Patients Who Were Lost to Follow-Up During Second-Line Tuberculosis Treatment in 2011-2014: Population-Based Study in the Country of Georgia. *Open Forum Infect Dis.* 2021;8(6):ofab127. <https://www.ncbi.nlm.nih.gov/pubmed/34189157>.
102. Kundu M, Basu J. The Role of microRNAs and Long Non-Coding RNAs in the Regulation of the Immune Response to Mycobacterium tuberculosis Infection. *Front Immunol.* 2021;12:687962. <https://www.ncbi.nlm.nih.gov/pubmed/34248974>.
103. Lara-Espinosa JV, Arce-Aceves MF, Mata-Espinosa D, Barrios-Payan J, Marquina-Castillo B, Hernandez-Pando R. The Therapeutic Effect of Intranasal Administration of Dexamethasone in Neuroinflammation Induced by Experimental Pulmonary Tuberculosis. *Int J Mol Sci.* 2021;22(11). <https://www.ncbi.nlm.nih.gov/pubmed/34206086>.
104. Lazzari TK, Cavaleiro E, Coutinho SE, da Silva LF, Silva DR. Leptin and advanced glycation end products receptor (RAGE) in tuberculosis patients. *PLoS One.* 2021;16(7):e0254198. <https://www.ncbi.nlm.nih.gov/pubmed/34214138>.
105. Le Hang NT, Hijikata M, Maeda S, Miyabayashi A, Wakabayashi K, Seto S, et al. Phenotypic and genotypic features of the Mycobacterium tuberculosis lineage 1 subgroup in central Vietnam. *Sci Rep.* 2021;11(1):13609. <https://www.ncbi.nlm.nih.gov/pubmed/34193941>.
106. Lee T, Lee SJ, Jeon D, Lee HY, Kim HJ, Kang BH, et al. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019. *J Korean Med Sci.* 2021;36(26):e174. <https://www.ncbi.nlm.nih.gov/pubmed/34227261>.
107. Li JL, Shi YN, Zhan LJ. [Establishment of an Iron-overloaded Mouse Model with Tuberculosis and Analysis of the Iron Metabolism Index]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.* 2021;43(3):357-65. <https://www.ncbi.nlm.nih.gov/pubmed/34238411>.
108. Li L, Li J, Chai C, Liu T, Li P, Qu M, et al. Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. *Int J Clin Exp Pathol.* 2021;14(6):670-9. <https://www.ncbi.nlm.nih.gov/pubmed/34239668>.
109. Li ZP, Mao WH, Huang F, Wang N, Ma LP, Zhang LQ, et al. Access to quality diagnosis and rational treatment for tuberculosis: real-world evidence from China-Gates Tuberculosis Control Project Phase III. *Infect Dis Poverty.* 2021;10(1):92. <https://www.ncbi.nlm.nih.gov/pubmed/34187558>.
110. Lin HS, Lin MS, Chi CC, Ye JJ, Hsieh CC. Nutrition Assessment and Adverse Outcomes in Hospitalized Patients with Tuberculosis. *J Clin Med.* 2021;10(12). <https://www.ncbi.nlm.nih.gov/pubmed/34207380>.
111. Liu ZM, Ai QY, Geng XW, Huang S, Wang JJ, Shi TY. [Pathogenesis of Secondary Pulmonary Tuberculosis and Role of Cord Factor in Secondary Infection]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.* 2021;43(3):452-61. <https://www.ncbi.nlm.nih.gov/pubmed/34238423>.

112. Lo CY, Huang YC, Huang HY, Chung FT, Lin CW, Chung KF, et al. Increased Th1 Cells with Disease Resolution of Active Pulmonary Tuberculosis in Non-Atopic Patients. *Biomedicines*. 2021;9(7). <https://www.ncbi.nlm.nih.gov/pubmed/34202662>.
113. Loiudice G, Catelli A, Corvino A, Quarantelli M, Venetucci P. Endovascular treatment of chronic hemoptysis in patients with pulmonary tuberculosis. *Acta Biomed*. 2021;92(3):e2021201. <https://www.ncbi.nlm.nih.gov/pubmed/34212920>.
114. Lopez A, Acosta F, Sambrano D, Tarajia M, Navajas S, Arias F, et al. Direct Molecular Characterization of Acid-Fast Bacilli Smear of Nontuberculosis Mycobacterium Species Causing Pulmonary Tuberculosis in Guna Yala Region, Panama. *Am J Trop Med Hyg*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34237018>.
115. Lu C, Jing H, Lu Z, Deng Y. Comparison of Different Methods for the Diagnosis of Mycobacterium Tuberculosis and Rifampin-Resistance. *Clin Lab*. 2021;67(7). <https://www.ncbi.nlm.nih.gov/pubmed/34258958>.
116. Lu P, Zhang Y, Liu Q, Ding X, Kong W, Zhu L, et al. Association of BMI, Diabetes, and Risk of Tuberculosis: a Population-Based Prospective Cohort. *Int J Infect Dis*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34217872>.
117. Lu Y, Chen Y, Peng X, Yao J, Zhong W, Li C, et al. Development and validation of a new algorithm model for differential diagnosis between Crohn's disease and intestinal tuberculosis: a combination of laboratory, imaging and endoscopic characteristics. *BMC Gastroenterol*. 2021;21(1):291. <https://www.ncbi.nlm.nih.gov/pubmed/34256708>.
118. Luna-Herrera J, Perez-Martinez DE, Barradas-Hernandez VM, Zenteno-Cuevas R. [Nanoparticles as drug transporters: a promising tool against tuberculosis]. *Rev Peru Med Exp Salud Publica*. 2021;38(1):143-52. <https://www.ncbi.nlm.nih.gov/pubmed/34190907>.
119. Ma S, Jones RM, Jr., Gleason NS, Farrow-Johnson J, Sherman DR. Experimental and Computational Workflow for RNA Sequencing in Mycobacterium tuberculosis : From Total RNA to Differentially Expressed Genes. *Methods Mol Biol*. 2021;2314:481-512. <https://www.ncbi.nlm.nih.gov/pubmed/34235667>.
120. Machmud PB, Gayatri D, Ronoatmodjo S. A Survival Analysis of Successful and Poor Treatment Outcome Among Patients with Drug-Resistant Tuberculosis and the Associated Factors: A Retrospective Cohort Study. *Acta Med Indones*. 2021;53(2):184-93. <https://www.ncbi.nlm.nih.gov/pubmed/34251347>.
121. Magalhaes CG, Moreira G, Ferreira MRA, Santos LMD, Finger PF, Ramos DF, et al. Novel phage display-derived recombinant antibodies recognizing both MPT64 native and mutant (63-bp deletion) are promising tools for tuberculosis diagnosis. *Biologicals*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34247914>.
122. Maitra A, Nukala S, Dickman R, Martin LT, Munshi T, Gupta A, et al. Characterization of the MurT/GatD complex in Mycobacterium tuberculosis towards validating a novel anti-tubercular drug target. *JAC Antimicrob Resist*. 2021;3(1):dlab028. <https://www.ncbi.nlm.nih.gov/pubmed/34223102>.

123. Mann TN, Warwick J, Chegou NN, Davis JH, Beltran CGG, Griffith-Richards S, et al. Biomarkers to predict FDG PET/CT activity after the standard duration of treatment for spinal tuberculosis: An exploratory study. *Tuberculosis (Edinb)*. 2021;129:102107. <https://www.ncbi.nlm.nih.gov/pubmed/34261033>.
124. Maokola WM, Ngowi BJ, Mahande MJ, Todd J, Robert M, Msuya SE. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania. *PLoS One*. 2021;16(7):e0254082. <https://www.ncbi.nlm.nih.gov/pubmed/34255776>.
125. Marchal B, Abejirinde IO, Sulaberidze L, Chikovani I, Uchaneishvili M, Shengelia N, et al. How do participatory methods shape policy? Applying a realist approach to the formulation of a new tuberculosis policy in Georgia. *BMJ Open*. 2021;11(6):e047948. <https://www.ncbi.nlm.nih.gov/pubmed/34187826>.
126. Maria Irene CC, Juan German RC, Gamaliel LL, Dulce Adriana ME, Estela Isabel B, Brenda Nohemi MC, et al. Profiling the immune response to Mycobacterium tuberculosis Beijing family infection: a perspective from the transcriptome. *Virulence*. 2021;12(1):1689-704. <https://www.ncbi.nlm.nih.gov/pubmed/34228582>.
127. Mason AB, Dartois V. Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor. *Methods Mol Biol*. 2021;2314:715-31. <https://www.ncbi.nlm.nih.gov/pubmed/34235677>.
128. Masuka JT, Mkhize Z, Pillay S, Mosam A. Concurrent pulmonary tuberculosis and lepromatous leprosy in a newly diagnosed HIV positive patient: a case report. *BMC Pulm Med*. 2021;21(1):207. <https://www.ncbi.nlm.nih.gov/pubmed/34193098>.
129. Medha, Sharma S, Sharma M. Proline-Glutamate/Proline-Proline-Glutamate (PE/PPE) proteins of Mycobacterium tuberculosis: The multifaceted immune-modulators. *Acta Trop*. 2021;222:106035. <https://www.ncbi.nlm.nih.gov/pubmed/34224720>.
130. Megerso A, Deyessa N, Jarso G, Tezera R, Worku A. Exploring community tuberculosis program in the pastoralist setting of Ethiopia: a qualitative study of community health workers' perspectives in Borena Zone, Oromia Region. *BMC Health Serv Res*. 2021;21(1):632. <https://www.ncbi.nlm.nih.gov/pubmed/34210297>.
131. Mercaldo R, Whalen C, Kakaire R, Nakkonde D, Handel A, Sekandi JN. Community drivers of tuberculosis diagnostic delay in Kampala, Uganda: a retrospective cohort study. *BMC Infect Dis*. 2021;21(1):641. <https://www.ncbi.nlm.nih.gov/pubmed/34217245>.
132. Mignani S, Bignon J, Shi X, Majoral JP. First-in-Class Phosphorus Dendritic Framework, a Wide Surface Functional Group Palette Bringing Noteworthy Anti-Cancer and Anti-Tuberculosis Activities: What Lessons to Learn? *Molecules*. 2021;26(12). <https://www.ncbi.nlm.nih.gov/pubmed/34204564>.

133. Mitini-Nkhoma SC, Chimbayo ET, Mzinza DT, Mhango DV, Chirambo AP, Mandalasi C, et al. Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents. *Front Immunol.* 2021;12:665785. <https://www.ncbi.nlm.nih.gov/pubmed/34248944>.
134. Mizukoshi F, Kobayashi N, Kirikae F, Ohta K, Tsuyuguchi K, Yamada N, et al. Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan. *mSphere.* 2021:e0097820. <https://www.ncbi.nlm.nih.gov/pubmed/34232083>.
135. Msoka EF, Orina F, Sanga ES, Miheso B, Mwanyonga S, Meme H, et al. Qualitative assessment of the impact of socioeconomic and cultural barriers on uptake and utilisation of tuberculosis diagnostic and treatment tools in East Africa: a cross-sectional study. *BMJ Open.* 2021;11(7):e050911. <https://www.ncbi.nlm.nih.gov/pubmed/34253677>.
136. Muhammed H, Jain A, Pattanaik SS, Chatterjee R, Naveen R, Kabeer H, et al. Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus. *Rheumatol Int.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34191047>.
137. Mukhatayeva A, Mustafa A, Dzissyuk N, Issanov A, Bayserkin B, Vermund SH, et al. Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan. *Sci Rep.* 2021;11(1):13542. <https://www.ncbi.nlm.nih.gov/pubmed/34188081>.
138. Murphy KC. Oligo-Mediated Recombineering and its Use for Making SNPs, Knockouts, Insertions, and Fusions in Mycobacterium tuberculosis. *Methods Mol Biol.* 2021;2314:301-21. <https://www.ncbi.nlm.nih.gov/pubmed/34235660>.
139. Myemba DT, Bwire GM, Sambayi G, Maganda BA, Njiro BJ, Ndumwa HP, et al. Clinical characteristics and treatment outcomes of patients with MDR tuberculosis in Dar Es Salaam region, Tanzania. *JAC Antimicrob Resist.* 2020;2(4):dlaa108. <https://www.ncbi.nlm.nih.gov/pubmed/34223058>.
140. Naia L, Rabadao T, Teixeira M, Ferreira F, Pinto S, Ferreira R, et al. Heart failure as a first sign of disseminated tuberculosis. *J Community Hosp Intern Med Perspect.* 2021;11(4):558-62. <https://www.ncbi.nlm.nih.gov/pubmed/34211669>.
141. Nathavitharana RR, Jijon DF, Pal P, Rane S. Diagnosing active tuberculosis in primary care. *BMJ.* 2021;374:n1590. <https://www.ncbi.nlm.nih.gov/pubmed/34210717>.
142. Neema S, Radhakrishnan S, Dabbas D, Vasudevan B. Latent Tuberculosis in Psoriasis Patients Planned for Systemic Therapy - A Prospective Observational Study. *Indian Dermatol Online J.* 2021;12(3):429-32. <https://www.ncbi.nlm.nih.gov/pubmed/34211910>.
143. Nguyen NTB, Le Ngoc H, Nguyen NV, Dinh LV, Nguyen HV, Nguyen HT, et al. Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study. *J Fungi (Basel).* 2021;7(7). <https://www.ncbi.nlm.nih.gov/pubmed/34209322>.
144. Nie D, Li J, Liu W, Wu Y, Ji M, Wang Y, et al. Esophagomediastinal fistula due to secondary esophageal tuberculosis: report of two cases. *J Int Med Res.* 2021;49(7):3000605211023696. <https://www.ncbi.nlm.nih.gov/pubmed/34256638>.

145. Nijjati M, Zhang Z, Abulizi A, Miao H, Tuluhong A, Quan S, et al. Deep learning assistance for tuberculosis diagnosis with chest radiography in low-resource settings. *J Xray Sci Technol*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34219703>.
146. Nilamsari WP, Rizqi MF, Regina NO, Wulaningrum PA, Fatmawati U. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study. *J Basic Clin Physiol Pharmacol*. 2021;32(4):783-7. <https://www.ncbi.nlm.nih.gov/pubmed/34214373>.
147. Notarfrancesco M, Castelnuovo B, Kaelin M, Fehr J, Sekaggya-Wiltshire C. 'Out of sight, out of mind?' A follow-up on HIV-infected patients with drug-resistant pulmonary tuberculosis in Uganda: A case series. *SAGE Open Med Case Rep*. 2021;9:2050313X211019790. <https://www.ncbi.nlm.nih.gov/pubmed/34211714>.
148. Obsa MS, Daga WB, Wosene NG, Gebremedhin TD, Edosa DC, Dedecho AT, et al. Treatment seeking delay and associated factors among tuberculosis patients attending health facility in Ethiopia from 2000 to 2020: A systematic review and meta analysis. *PLoS One*. 2021;16(7):e0253746. <https://www.ncbi.nlm.nih.gov/pubmed/34197515>.
149. Odhiambo CO, Mataka A, Massinga Loembe M, Ondoa P. Maintaining routine HIV and tuberculosis testing services in sub-Saharan African countries in the context of COVID-19: Lessons learnt and opportunities for improvement. *Afr J Lab Med*. 2021;10(1):1413. <https://www.ncbi.nlm.nih.gov/pubmed/34230879>.
150. Ok V, Aubry A, Morel F, Bonnet I, Robert J, Sougakoff W. Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITE MGB((R)) Assay. *Antibiotics (Basel)*. 2021;10(7). <https://www.ncbi.nlm.nih.gov/pubmed/34208899>.
151. Ordaz-Vazquez A, Torres-Gonzalez P, Cruz-Hervert P, Ferreyra-Reyes L, Delgado-Sanchez G, Garcia-Garcia L, et al. Genetic diversity and primary drug resistance transmission in Mycobacterium tuberculosis in southern Mexico. *Infect Genet Evol*. 2021;93:104994. <https://www.ncbi.nlm.nih.gov/pubmed/34245908>.
152. Oudghiri A, Momen G, Aainouss A, Laglaoui A, El Messaoudi MD, El Mzibri M, et al. Genotypic diversity of multi- and pre-extremely drug-resistant Mycobacterium tuberculosis isolates from Morocco. *PLoS One*. 2021;16(7):e0253826. <https://www.ncbi.nlm.nih.gov/pubmed/34214120>.
153. Pan J, Ye H, Wu Z, Xiao J, Liu J. Correction to: One-step melting curve analysis-based McSpoligotyping reveals genotypes of Mycobacterium tuberculosis in a coastal city, China. *Arch Microbiol*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34255125>.
154. Parihar SP, Ozturk M, Hoft MA, Chia JE, Guler R, Keeton R, et al. IL-4-Responsive B Cells Are Detrimental During Chronic Tuberculosis Infection in Mice. *Front Immunol*. 2021;12:611673. <https://www.ncbi.nlm.nih.gov/pubmed/34220793>.

155. Parmer J, Macario E, Tatum K, Brackett A, Allen L, Picard R, et al. Latent tuberculosis infection: Misperceptions among non-U.S.-born-populations from countries where tuberculosis is common. *Glob Public Health*. 2021;1-15. <https://www.ncbi.nlm.nih.gov/pubmed/34228584>.
156. Pavlovic JM, Pesut DP, Stosic MB. Influence of the COVID-19 pandemic on the incidence of tuberculosis and influenza. *Rev Inst Med Trop Sao Paulo*. 2021;63:e53. <https://www.ncbi.nlm.nih.gov/pubmed/34190955>.
157. Pecerska J, Kuhnert D, Meehan CJ, Coscolla M, de Jong BC, Gagneux S, et al. Quantifying transmission fitness costs of multi-drug resistant tuberculosis. *Epidemics*. 2021;36:100471. <https://www.ncbi.nlm.nih.gov/pubmed/34256273>.
158. Pedersen JL, Barry SE, Bokil NJ, Ellis M, Yang Y, Guan G, et al. High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis. *Clin Transl Immunology*. 2021;10(6):e1298. <https://www.ncbi.nlm.nih.gov/pubmed/34188917>.
159. Peetluk LS, Rebeiro PF, Ridolfi FM, Andrade BB, Cordeiro-Santos M, Kritski A, et al. A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. *Clin Infect Dis*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34214166>.
160. Pellegrini JM, Martin C, Morelli MP, Schander JA, Tateosian NL, Amiano NO, et al. PGE2 displays immunosuppressive effects during human active tuberculosis. *Sci Rep*. 2021;11(1):13559. <https://www.ncbi.nlm.nih.gov/pubmed/34193890>.
161. Phiri MM, Makepeace E, Nyali M, Kumwenda M, Corbett L, Fielding K, et al. Improving pathways to care through interventions cocreated with communities: a qualitative investigation of men's barriers to tuberculosis care-seeking in an informal settlement in Blantyre, Malawi. *BMJ Open*. 2021;11(6):e044944. <https://www.ncbi.nlm.nih.gov/pubmed/34193484>.
162. Piergallini TJ, Scordo JM, Pino PA, Schlesinger LS, Torrelles JB, Turner J. Acute Inflammation Confers Enhanced Protection against Mycobacterium tuberculosis Infection in Mice. *Microbiol Spectr*. 2021:e0001621. <https://www.ncbi.nlm.nih.gov/pubmed/34232086>.
163. Pithwa YK, Sinha Roy V. Can We Extrapolate SINS Score to Evaluate Instability in Spinal Tuberculosis? *Global Spine J*. 2021:21925682211030876. <https://www.ncbi.nlm.nih.gov/pubmed/34259089>.
164. Planck KA, Rhee K. Metabolomics of Mycobacterium tuberculosis. *Methods Mol Biol*. 2021;2314:579-93. <https://www.ncbi.nlm.nih.gov/pubmed/34235671>.
165. Puchalski Ritchie LM, Kip EC, Mundeve H, van Lettow M, Makwakwa A, Straus SE, et al. Process evaluation of an implementation strategy to support uptake of a tuberculosis treatment adherence intervention to improve TB care and outcomes in Malawi. *BMJ Open*. 2021;11(7):e048499. <https://www.ncbi.nlm.nih.gov/pubmed/34215610>.
166. Qadir M, Tahseen S, McHugh TD, Hussain A, Masood F, Ahmed N, et al. Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan. *J Infect Chemother*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34244055>.



167. Quiroz-Ruiz HR, Sosa-Flores JL, Hernandez-Palomino FN. [Underreporting and exhaustiveness of tuberculosis surveillance systems in a region of Peru: a capture-recapture analysis]. *Cad Saude Publica*. 2021;37(6):e00276020. <https://www.ncbi.nlm.nih.gov/pubmed/34190834>.
168. Rafique A, Rasheed R, Shamim S, Ijaz M, Murtaza G. A Review on Nuclear Imaging as a Promising Modality for Efficient Diagnosis of Tuberculosis. *Curr Med Imaging*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34238164>.
169. Raine R. Screening for pulmonary hypertension secondary to pulmonary tuberculosis. *Afr J Thorac Crit Care Med*. 2020;26(4). <https://www.ncbi.nlm.nih.gov/pubmed/34240032>.
170. Rajasekhar S, Karuppasamy R, Chanda K. Exploration of potential inhibitors for tuberculosis via structure-based drug design, molecular docking, and molecular dynamics simulation studies. *J Comput Chem*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34216033>.
171. Rao PS, Moore CC, Mbonde AA, Nuwagira E, Orikiriza P, Nyehangane D, et al. Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness. *Antibiotics (Base)*. 2021;10(6). <https://www.ncbi.nlm.nih.gov/pubmed/34207312>.
172. Raviglione MC, Rieder HL. Synergy between government and non-governmental organizations in health: WHO and the Union collaboration in tuberculosis control. *J Clin Tuberc Other Mycobact Dis*. 2021;24:100251. <https://www.ncbi.nlm.nih.gov/pubmed/34195387>.
173. Razem B, El Hamid S, Salissou I, Raiteb M, Slimani F. Lingual primary tuberculosis mimicking malignancy. *Ann Med Surg (Lond)*. 2021;67:102525. <https://www.ncbi.nlm.nih.gov/pubmed/34194736>.
174. Rendon-Bautista LA, Alvarez-Maya I, Sandoval-Diaz M, Villanueva-Arias JC, Ayala-Chavira N, Zenteno-Cuevas R. Characterization of genetic diversity and clonal complexes by whole genome sequencing of Mycobacterium tuberculosis isolates from Jalisco, Mexico. *Tuberculosis (Edinb)*. 2021;129:102106. <https://www.ncbi.nlm.nih.gov/pubmed/34218194>.
175. Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin-resistant Mycobacterium tuberculosis in Ethiopia: A systematic review and meta-analysis. *J Glob Antimicrob Resist*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34214698>.
176. Reyes-Paredes M, Valladares-Garrido MJ, Ichiro Peralta C, Dominguez-Troncos H, Grandez-Urbina A. Factors associated with high-grade Erectile Dysfunction (ED) in tuberculosis patients from a hospital in Lima, Peru. *Arch Esp Urol*. 2021;74(6):579-86. <https://www.ncbi.nlm.nih.gov/pubmed/34219060>.
177. Riskiyev A, Ciobanu A, Hovhannesyanyan A, Akopyan K, Gadoev J, Parpieva N. Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan. *Int J Environ Res Public Health*. 2021;18(12). <https://www.ncbi.nlm.nih.gov/pubmed/34204519>.

178. Sahiratmadja E, Rini IA, Penggoam S, Charles A, Maskoen AM, Parwati I. Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia. *Pharmgenomics Pers Med.* 2021;14:737-44. <https://www.ncbi.nlm.nih.gov/pubmed/34188520>.
179. Salindri AD, Haw JS, Amere GA, Alese JT, Umpierrez GE, Magee MJ. Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta. *BMC Res Notes.* 2021;14(1):252. <https://www.ncbi.nlm.nih.gov/pubmed/34193265>.
180. Sampath P, Periyasamy KM, Ranganathan UD, Bethunaickan R. Monocyte and Macrophage miRNA: Potent Biomarker and Target for Host-Directed Therapy for Tuberculosis. *Front Immunol.* 2021;12:667206. <https://www.ncbi.nlm.nih.gov/pubmed/34248945>.
181. Samuels THA, Wyss R, Ongarello S, Moore DAJ, Schumacher SG, Denkinger CM. Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis. *PLoS One.* 2021;16(7):e0254002. <https://www.ncbi.nlm.nih.gov/pubmed/34252128>.
182. Sanhueza-Sanzana C, Kerr L, Kendall C. Mortality from AIDS and tuberculosis-HIV coinfection in the Chilean AIDS Cohort of 2000-2017. *Cad Saude Publica.* 2021;37(6):e00212920. <https://www.ncbi.nlm.nih.gov/pubmed/34190832>.
183. Sanoussi CN, Coscolla M, Ofori-Anyinam B, Otchere ID, Antonio M, Niemann S, et al. Mycobacterium tuberculosis complex lineage 5 exhibits high levels of within-lineage genomic diversity and differing gene content compared to the type strain H37Rv. *Microb Genom.* 2021;7(7). <https://www.ncbi.nlm.nih.gov/pubmed/34241588>.
184. Schwarz DGG, de Sousa Junior PF, Saraiva da Silva L, Polveiro RC, de Oliveira JF, Faria MPO, et al. Spatiotemporal distribution and temporal trends of brucellosis and tuberculosis in water buffalo (*Bubalus bubalis*) in Brazil. *Prev Vet Med.* 2021;193:105417. <https://www.ncbi.nlm.nih.gov/pubmed/34192652>.
185. Seegert AB, Patsche CB, Sifna A, Gomes VF, Wejse C, Storgaard M, et al. Hypertension is associated with increased mortality in patients with tuberculosis in Guinea-Bissau. *Int J Infect Dis.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34224869>.
186. Selimin DS, Ismail A, Ahmad N, Ismail R, Mohd Azman NF, Azman A. Tuberculosis Treatment Outcome in Patients with TB-HIV Coinfection in Kuala Lumpur, Malaysia. *J Trop Med.* 2021;2021:9923378. <https://www.ncbi.nlm.nih.gov/pubmed/34194511>.
187. Sharma R, Rajput VS, Jamal S, Grover A, Grover S. An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins. *Sci Rep.* 2021;11(1):13836. <https://www.ncbi.nlm.nih.gov/pubmed/34226593>.
188. Shayo FK, Shayo SC. Readiness of healthcare facilities with tuberculosis services to manage diabetes mellitus in Tanzania: A nationwide analysis for evidence-informed policy-making in high burden settings. *PLoS One.* 2021;16(7):e0254349. <https://www.ncbi.nlm.nih.gov/pubmed/34252144>.


189. Shewade HD, Nagaraja SB, Murthy HJD, Vanitha B, Bhargava M, Singarajipura A, et al. Screening People with Tuberculosis for High Risk of Severe Illness at Notification: Programmatic Experience from Karnataka, India. *Trop Med Infect Dis.* 2021;6(2). <https://www.ncbi.nlm.nih.gov/pubmed/34203984>.
190. Shtaya A, Thomas M, Sampson MM, Giannoulis K, Nader-Sepahi A. Resolving solitary osteolytic lumbar tuberculosis in young adult. *Br J Neurosurg.* 2021:1-4. <https://www.ncbi.nlm.nih.gov/pubmed/34251952>.
191. Shu-Yip S, Wong M, Iverson KR, Roa L, Lecca L, Sotomayor A, et al. Referral Process for Surgical Management of Tuberculosis in Lima: A Qualitative Study. *J Surg Res.* 2021;267:384-90. <https://www.ncbi.nlm.nih.gov/pubmed/34225051>.
192. Singh A, Mittal D, Jain V, Kabra SK, Agarwala S. Primary Esophageal Tuberculosis. *Indian J Pediatr.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34251557>.
193. Singh V, Dziwornu GA, Mabhula A, Chibale K. Rv0684/fusA1, an Essential Gene, Is the Target of Fusidic Acid and Its Derivatives in Mycobacterium tuberculosis. *ACS Infect Dis.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34196521>.
194. Smith A, Herington E, Loshak H. Tuberculosis Stigma and Racism, Colonialism, and Migration: A Rapid Qualitative Review. *CADTH Health Technology Review.* Ottawa (ON)2021. <https://www.ncbi.nlm.nih.gov/pubmed/34260166>.
195. Sohni D. Pancreatic Mass: Include Tuberculosis in the Differential Diagnosis. *Cureus.* 2021;13(6):e15430. <https://www.ncbi.nlm.nih.gov/pubmed/34249575>.
196. Sousa G, Pascoal LM, Costa A, Santos FS, Santos LHD, Arcencio RA, et al. Trend and factors associated with Tuberculosis-Diabetes Mellitus comorbidity in a Northeastern Brazilian municipality. *Rev Bras Enferm.* 2021;74(3):e20201238. <https://www.ncbi.nlm.nih.gov/pubmed/34259732>.
197. Spiegel JM, Ehrlich R, Yassi A, Riera F, Wilkinson J, Lockhart K, et al. Using Artificial Intelligence for High-Volume Identification of Silicosis and Tuberculosis: A Bio-Ethics Approach. *Ann Glob Health.* 2021;87(1):58. <https://www.ncbi.nlm.nih.gov/pubmed/34249620>.
198. Starshinova A, Guglielmetti L, Rzhepishevskaya O, Ekaterincheva O, Zinchenko Y, Kudlay D. Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). *J Clin Tuberc Other Mycobact Dis.* 2021;24:100259. <https://www.ncbi.nlm.nih.gov/pubmed/34235277>.
199. Stefanescu S, Cocos R, Turcu-Stiolica A, Shelby ES, Matei M, Subtirelu MS, et al. Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results. *Pathogens.* 2021;10(7). <https://www.ncbi.nlm.nih.gov/pubmed/34206598>.

200. Stosic MB, Sagic L, Simic D, Jovanovic V, Rakic V, Adzic Vukicevic T. Tuberculosis and associated risk factors among children and adolescent population in Serbia: 12 year's retrospective study. *J Infect Dev Ctries.* 2021;15(6):818-25. <https://www.ncbi.nlm.nih.gov/pubmed/34242192>.
201. Stutz MD, Allison CC, Ojaimi S, Preston SP, Doerflinger M, Arandjelovic P, et al. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis. *Immunity.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34256013>.
202. Subbaraman R, Thomas BE, Kumar JV, Thiruvengadam K, Khandewale A, Kokila S, et al. Understanding Nonadherence to Tuberculosis Medications in India Using Urine Drug Metabolite Testing: A Cohort Study. *Open Forum Infect Dis.* 2021;8(6):ofab190. <https://www.ncbi.nlm.nih.gov/pubmed/34250181>.
203. Suby JA. The pathway of tuberculosis in Argentina: Historical (19th and 20th centuries), epidemiological, and paleopathological data. *Int J Paleopathol.* 2021;34:82-9. <https://www.ncbi.nlm.nih.gov/pubmed/34218135>.
204. Sural S, Soni A, Kashyap A, Ahmad V, Hanif M, Khanna A. Spectrum of Drug Resistance in Musculoskeletal Tuberculosis. *Indian J Orthop.* 2021;55(4):907-11. <https://www.ncbi.nlm.nih.gov/pubmed/34194646>.
205. Suryakusumah L, Tabri NA, Saleh S, Bakri S, Kasim H, Benyamin AF, et al. Hemostatic parameters in pulmonary tuberculosis patients after intensive phase treatment. *Caspian J Intern Med.* 2021;12(3):294-8. <https://www.ncbi.nlm.nih.gov/pubmed/34221279>.
206. Swain SS, Hussain T, Pati S. Drug-Lead Anti-tuberculosis Phytochemicals: A Systematic Review. *Curr Top Med Chem.* 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34225624>.
207. Tabbasum S, Majeed MI, Nawaz H, Rashid N, Tahira M, Mohsin A, et al. Surface-Enhanced Raman Spectroscopy for Comparison of Serum Samples of Typhoid and Tuberculosis Patients of Different Stages. *Photodiagnosis Photodyn Ther.* 2021:102426. <https://www.ncbi.nlm.nih.gov/pubmed/34217869>.
208. Tafess K, Beyen TK, Girma S, Girma A, Siu G. Spatial clustering and genetic diversity of Mycobacterium tuberculosis isolate among pulmonary tuberculosis suspected patients, Arsi Zone, Ethiopia. *BMC Pulm Med.* 2021;21(1):206. <https://www.ncbi.nlm.nih.gov/pubmed/34193091>.
209. Taghipour A, Malih N, Koksai F, Jokelainen P, Ghaffarifar F. Toxoplasma gondii seroprevalence among tuberculosis patients: A systematic review and meta-analysis. *Microb Pathog.* 2021:105083. <https://www.ncbi.nlm.nih.gov/pubmed/34246749>.
210. Tan Y, Tan Y, Li J, Hu P, Guan P, Kuang H, et al. Combined IFN-gamma and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China. *J Transl Med.* 2021;19(1):289. <https://www.ncbi.nlm.nih.gov/pubmed/34217302>.

211. Taye H, Alemu K, Mihret A, Ayalew S, Hailu E, Wood JLN, et al. Epidemiology of Mycobacterium tuberculosis lineages and strain clustering within urban and peri-urban settings in Ethiopia. *PLoS One*. 2021;16(7):e0253480. <https://www.ncbi.nlm.nih.gov/pubmed/34252107>.
212. Terzi O, Oztomurcuk D, Gun S, Kilicaslan Z. Evaluation of effectiveness of pathology reports in active surveillance of tuberculosis. *Cent Eur J Public Health*. 2021;29(2):96-101. <https://www.ncbi.nlm.nih.gov/pubmed/34245548>.
213. Tian Y, Zhang Y, Wen B, Li C, He Y. Hepatosplenic tuberculosis on (18)F-FDG PET/CT imaging in a patient with Pyrexia of Unknown Origin. *Rev Esp Med Nucl Imagen Mol (Engl Ed)*. 2021;40(4):267-9. <https://www.ncbi.nlm.nih.gov/pubmed/34218896>.
214. Timire C, Ngwenya M, Chirenda J, Metcalfe JZ, Kranzer K, Pedrazzoli D, et al. Catastrophic costs among tuberculosis affected households in Zimbabwe: a national health facility-based survey. *Trop Med Int Health*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34192392>.
215. Tippalagama R, Singhania A, Dubelko P, Lindestam Arlehamn CS, Crinklaw A, Pomaznoy M, et al. HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. *J Immunol*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34193602>.
216. Tocco-Tussardi I, Fila A, Tralli V, Bordin P, Gazzani D, Majori S, et al. Screening for hepatitis B virus infection among refugees diagnosed with latent tuberculosis in an Italian community. *Ann Ig*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34213522>.
217. Torpiano P, Holwill S, Pace D. Mesangiocapillary glomerulonephritis complicating pulmonary tuberculosis. *CEN Case Rep*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34260011>.
218. Torres-Pascual C, Sanchez-Perez HJ, Avila-Castells P. Geographical distribution and international collaboration of Latin American and Caribbean scientific publications on tuberculosis in Pubmed. *Rev Peru Med Exp Salud Publica*. 2021;38(1):49-57. <https://www.ncbi.nlm.nih.gov/pubmed/34190923>.
219. Truax FN, Low J, Mochizuki T, Asfaha S, Nguyen TN, Carson M, et al. Latent Tuberculosis Infection Testing and Treatment at a Federally Qualified Health Center in Southern California: A Quality Improvement Project. *J Nurs Care Qual*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34261089>.
220. van Alen I, Chikunova A, Safeer AA, Ahmad MUD, Perrakis A, Ubbink M. The G132S Mutation Enhances the Resistance of Mycobacterium tuberculosis beta-Lactamase against Sulbactam. *Biochemistry*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34250791>.
221. Vangone L, Cardillo L, Riccardi MG, Borriello G, Cerrone A, Coppa P, et al. Mycobacterium tuberculosis SIT42 Infection in an Abused Dog in Southern Italy. *Front Vet Sci*. 2021;8:653360. <https://www.ncbi.nlm.nih.gov/pubmed/34239909>.
222. Verma A, Radotra BD, Sharma S. Role of resuscitation promoting factors in reactivation of latent tuberculosis during high glucose conditions employing human granuloma in vitro model. *Microb Pathog*. 2021:105068. <https://www.ncbi.nlm.nih.gov/pubmed/34245822>.

223. Wademan DT, Mainga T, Gondwe M, Ayles H, Shanaube K, Mureithi L, et al. 'TB is a disease which hides in the body': Qualitative data on conceptualisations of tuberculosis recurrence among patients in Zambia and South Africa. *Glob Public Health*. 2021:1-15. <https://www.ncbi.nlm.nih.gov/pubmed/34187320>.
224. Wang Y, Dou M, Kou T, Liu Y, Lv W, Han L, et al. Risk of having pulmonary tuberculosis in type 2 diabetes: A hospital-based matched case-control study. *Asia Pac J Clin Nutr*. 2021;30(2):303-10. <https://www.ncbi.nlm.nih.gov/pubmed/34191433>.
225. Wedy GF, Passero LFD, Criado PR, Junior WB. A case of tuberculosis verrucosa cutis in Brazil undiagnosed for 15 years. *Braz J Infect Dis*. 2021:101593. <https://www.ncbi.nlm.nih.gov/pubmed/34242596>.
226. Weir IR, Wasserman S. Treatment effect measures for culture conversion endpoints in phase IIb tuberculosis treatment trials. *Clin Infect Dis*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34254635>.
227. Wells C, Severn M. Incentives and Support Programs to Improve Adherence to Tuberculosis Treatment. CADTH Health Technology Review. *Ottawa (ON)*2021. <https://www.ncbi.nlm.nih.gov/pubmed/34197058>.
228. Wennergren G, Lagercrantz H. Arvid Wallgren: Made important progress in the field of tuberculosis. *Acta Paediatr*. 2021;110 Suppl 472:12-3. <https://www.ncbi.nlm.nih.gov/pubmed/34240771>.
229. Winglee K, McDaniel CJ, Linde L, Kammerer S, Cilnis M, Raz KM, et al. Logically Inferred Tuberculosis Transmission (LITT): A Data Integration Algorithm to Rank Potential Source Cases. *Front Public Health*. 2021;9:667337. <https://www.ncbi.nlm.nih.gov/pubmed/34235130>.
230. Wu L, Cheng Q, Wen Z, Song Y, Zhu Y, Wang L. IRF1 as a potential biomarker in Mycobacterium tuberculosis infection. *J Cell Mol Med*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34213077>.
231. Yadav J, John D, Allarakha S, Menon GR. Rising healthcare expenditure on tuberculosis in India: Can India achieve the End-Tb goal? *Trop Med Int Health*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34192385>.
232. Yan M, Puyat JH, Shulha HP, Clark EG, Levin A, Johnston JC. Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. *Nephrol Dial Transplant*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34260735>.
233. Yang QY, Liu YJ, Ye X, Zhang L, Wang CD. The monitoring frequency of Interferon Gamma Release Assay for tuberculosis surveillance following Infliximab therapy in patients with Crohn's disease. *J Dig Dis*. 2021. <https://www.ncbi.nlm.nih.gov/pubmed/34240823>.
234. Yu S, Sohn H, Kim HY, Kim H, Oh KH, Kim HJ, et al. Evaluating the impact of the nationwide public-private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis. *PLoS Med*. 2021;18(7):e1003717. <https://www.ncbi.nlm.nih.gov/pubmed/34260579>.

235. Yuen CM, Puma D, Millones AK, Galea JT, Tzelios C, Calderon RI, et al. Identifying barriers and facilitators to implementation of community-based tuberculosis active case finding with mobile X-ray units in Lima, Peru: a RE-AIM evaluation. *BMJ Open*. 2021;11(7):e050314. <https://www.ncbi.nlm.nih.gov/pubmed/34234000>.
236. Zhang L, Wan S, Zhou Z, Zhang Y, Liu X. Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active tuberculosis and latent tuberculosis infection: a pilot study. *BMC Infect Dis*. 2021;21(1):651. <https://www.ncbi.nlm.nih.gov/pubmed/34225667>.
237. Zhong W, Bragazzi NL, Kong JD, Safiri S, Behzadifar M, Liu J, et al. Burden of Respiratory Infection and Tuberculosis Among US States from 1990 to 2019. *Clin Epidemiol*. 2021;13:503-14. <https://www.ncbi.nlm.nih.gov/pubmed/34234569>.
238. Zhu B, Tang J, Fang R, Fei X, Wang Q, Wang W, et al. Pulmonary coinfection of *Mycobacterium tuberculosis* and *Tropheryma whipplei*: a case report. *J Med Case Rep*. 2021;15(1):359. <https://www.ncbi.nlm.nih.gov/pubmed/34243811>.
239. Zimmer AJ, Heitkamp P, Malar J, Dantas C, O'Brien K, Pandita A, et al. Facility-based directly observed therapy (DOT) for tuberculosis during COVID-19: A community perspective. *J Clin Tuberc Other Mycobact Dis*. 2021;24:100248. <https://www.ncbi.nlm.nih.gov/pubmed/34189276>.
240. Zimmer AJ, Schumacher SG, Sodersten E, Mantsoki A, Wyss R, Persing DH, et al. A novel blood-based assay for treatment monitoring of tuberculosis. *BMC Res Notes*. 2021;14(1):247. <https://www.ncbi.nlm.nih.gov/pubmed/34193258>.



our other publications...



NIRT Library  
National Institute for Research in Tuberculosis  
(Indian Council of Medical Research)  
1, Mayor Sathyamoorthy Road  
Chetpet, Chennai 600031  
Tel: 91 44 28369637 | Fax: 91 44 28362525  
Email: [nirtlibrary@nirt.res.in](mailto:nirtlibrary@nirt.res.in)